Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
03/06/2024 | 16:22 | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
29/05/2024 | 14:05 | RNS Regulatory News | MaxCyte, Inc. Participation in Upcoming Investor Conference | LSE:MXCT | Maxcyte Inc |
22/05/2024 | 22:51 | Alliance News | IN BRIEF: MaxCyte inks deal with Legend Biotech for tech supply | LSE:MXCT | Maxcyte Inc |
22/05/2024 | 14:05 | RNS Regulatory News | MaxCyte, Inc. Signing of Strategic Platform License | LSE:MXCT | Maxcyte Inc |
20/05/2024 | 08:00 | RNS Regulatory News | MaxCyte, Inc. Holding(s) in Company | LSE:MXCT | Maxcyte Inc |
08/05/2024 | 10:46 | Alliance News | MaxCyte shares rise amid double-digit revenue increase | LSE:MXCT | Maxcyte Inc |
08/05/2024 | 08:05 | RNS Regulatory News | MaxCyte, Inc. Filing of Form 10-Q | LSE:MXCT | Maxcyte Inc |
08/05/2024 | 08:00 | RNS Regulatory News | MaxCyte, Inc. First Quarter Results | LSE:MXCT | Maxcyte Inc |
03/05/2024 | 08:00 | RNS Regulatory News | MaxCyte, Inc. Notice of AGM | LSE:MXCT | Maxcyte Inc |
10/04/2024 | 14:05 | RNS Regulatory News | MaxCyte, Inc. Notice of Results | LSE:MXCT | Maxcyte Inc |
03/04/2024 | 08:00 | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights and Block Listing Return | LSE:MXCT | Maxcyte Inc |
02/04/2024 | 16:19 | Alliance News | TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout | LSE:MXCT | Maxcyte Inc |
02/04/2024 | 08:00 | RNS Regulatory News | MaxCyte, Inc. Exercise of options and PDMR dealing | LSE:MXCT | Maxcyte Inc |
20/03/2024 | 11:16 | RNS Regulatory News | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing | LSE:MXCT | Maxcyte Inc |
13/03/2024 | 12:54 | Alliance News | IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25% | LSE:MXCT | Maxcyte Inc |
13/03/2024 | 08:05 | RNS Regulatory News | MaxCyte, Inc. Filing of form 10-K for FY ended December 31, 2023 | LSE:MXCT | Maxcyte Inc |
13/03/2024 | 08:00 | RNS Regulatory News | MaxCyte, Inc. Reports Q4 & FY 2023 Financial Results | LSE:MXCT | Maxcyte Inc |
12/03/2024 | 21:05 | UK Regulatory | MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance | LSE:MXCT | Maxcyte Inc |
06/03/2024 | 09:58 | RNS Regulatory News | MaxCyte, Inc. TR-1: Notification of major holdings | LSE:MXCT | Maxcyte Inc |
05/03/2024 | 21:43 | Alliance News | EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit | LSE:MXCT | Maxcyte Inc |
05/03/2024 | 08:00 | RNS Regulatory News | MaxCyte, Inc. Preliminary FY Results & 2024 Guidance | LSE:MXCT | Maxcyte Inc |
04/03/2024 | 22:05 | UK Regulatory | MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results | LSE:MXCT | Maxcyte Inc |
09/02/2024 | 14:05 | UK Regulatory | MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences | LSE:MXCT | Maxcyte Inc |
31/01/2024 | 08:00 | RNS Regulatory News | MaxCyte, Inc. Director/PDMR Shareholding | LSE:MXCT | Maxcyte Inc |
30/01/2024 | 14:58 | Alliance News | IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen | LSE:MXCT | Maxcyte Inc |
30/01/2024 | 14:05 | UK Regulatory | MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers | LSE:MXCT | Maxcyte Inc |
29/01/2024 | 18:56 | Alliance News | IN BRIEF: MaxCyte chief scientific officer leaves firm | LSE:MXCT | Maxcyte Inc |
29/01/2024 | 08:00 | RNS Regulatory News | MaxCyte, Inc. Filing of Form 8-K | LSE:MXCT | Maxcyte Inc |
23/01/2024 | 19:39 | Alliance News | TRADING UPDATES: Esken's Southend Airport faces further allegations | LSE:MXCT | Maxcyte Inc |
09/01/2024 | 13:18 | Alliance News | MaxCyte's strategic platform licences redeem otherwise modest results | LSE:MXCT | Maxcyte Inc |